Last reviewed · How we verify
sugammadex 10 min after position change
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade.
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery.
At a glance
| Generic name | sugammadex 10 min after position change |
|---|---|
| Also known as | restricted dose of rocuronium |
| Sponsor | Korea University Guro Hospital |
| Drug class | Selective relaxant binding agent |
| Target | Rocuronium and vecuronium (neuromuscular blocking agents) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Perioperative Medicine |
| Phase | FDA-approved |
Mechanism of action
Sugammadex forms a tight 1:1 complex with steroidal neuromuscular blocking agents (rocuronium and vecuronium) through host-guest chemistry, effectively removing them from the neuromuscular junction and plasma. This allows acetylcholine to restore normal neuromuscular transmission without requiring acetylcholinesterase inhibitors. The timing notation '10 min after position change' appears to refer to a specific clinical protocol for administration timing post-operatively.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
Common side effects
- Bradycardia
- Hypotension
- Nausea
- Vomiting
- Recurarization
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: